Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US

    Phase 2 study of VX-659 combination drug in adults with cystic fibrosis. , protocol number VX16-659-101

    This study is taking place at multiple care centres across the US. It will look at the safety and effectiveness of the drug VX-659.

    • Age:

      18 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      6

    • Length of Participation:

      8 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    A Study to evaluate tezacaftor/ivacaftor and ivacaftor in adults with cystic fibrosis and two copies of the F508del mutation. , protocol number NCT031 50719 VX16-661-114

    This randomized, placebo-controlled study is taking place at multiple care centers across the U.S. This study will look at the safety, effectiveness, and tolerability of the drug tezacaftor/ivacaftor in combination with ivacaftor.

    • Age:

      12 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      25% - 90%

    • Number of Visits:

      5

    • Length of Participation:

      84 days

    Contact us about this clinical Trial >
  • Mucociliary ClearanceCompleted with results Location: USA

    Phase 2 study of VX-371 in people with CF who are currently taking lumacaftor/ivacaftor , protocol number Vertex VX-371-101

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the inhaled drug VX-371 (formerly P-1037) and will use a placebo control.

    • Age:

      12 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      12

    • Length of Participation:

      98 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA

    VX-661 alone and in combination with ivacaftor in people with cystic fibrosis , protocol number Vertex VX11-661-101

    This study is taking place at multiple care centers across the U.S. It looked at the safety and effectiveness of VX-661 alone and in combination with ivacaftor, as well as how the drug works in the body, in people with CF.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      9

    • Length of Participation:

      84 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA

    Study of VX-661 combined with ivacaftor in adults with cystic fibrosis , protocol number Vertex VX13-661-103

    This study evaluated the safety and the best way to dose VX-661 in combination with ivacaftor. This study was for adults with CF who have two copies of the F508del CFTR mutation.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      8

    • Length of Participation:

      20 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: USA

    Phase 3 study of VX-661 and ivacaftor in people with cystic fibrosis. , protocol number Vertex VX-661-106

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug VX-661 in combination with ivacaftor in people with CF.

    • Age:

      12 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      11

    • Length of Participation:

      32 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA

    Phase 3 study of Vertex 661 and ivacaftor in people with CF who have one copy of the F508del-CFTR mutation and a second CFTR mutation predicted to have residual function. , protocol number Vertex NCT02392234 VX14-661-108

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug VX-661 in combination with ivacaftor and will use a placebo control.

    • Age:

      12 Years and Older

    • Mutation(s):

      One Copy F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      12

    • Length of Participation:

      33 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA

    Phase 3 study of Vertex and ivacaftor in people with cystic fibrosis , protocol number Vertex VX-661-107

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug VX-661 in combination with ivacaftor and will use a placebo control.

    • Age:

      12 Years and Older

    • Mutation(s):

      One Copy F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      8

    • Length of Participation:

      25 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA

    Phase 3 study of Vertex 661 and ivacaftor in people with CF who have one copy of the F508del-CFTR mutation and a second CFTR mutation with a gating defect responsive to ivacaftor. , protocol number Vertex VX-661-109

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug VX-661 in combination with inacaftor and will use a placebo control.

    • Age:

      12 Years and Older

    • Mutation(s):

      One Copy F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      8

    • Length of Participation:

      13

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US

    Study of VX-661 plus ivacaftor in people with CF who have two copies of the F508del CFTR mutation. , protocol number Vertex VX-661-11

    This study evaluated the safety and effectiveness of the CFTR modulator drug VX-661 in combination with ivacaftor (Symdeko®). This study was for people with CF who have two copies of the F508del CFTR mutation.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      6

    • Length of Participation:

      60 days

    Contact us about this clinical Trial >
  • Displaying results 151-160 (of 168)
     |<  <  8 - 9 - 10 - 11 - 12 - 13 - 14 - 15 - 16 - 17  >  >|